Cite this answer
Cerebrolysin: quick citable summary
Cerebrolysin is listed by PeptaHub as a cognitive peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Cerebrolysin: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/cerebrolysin. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/cerebrolysin.
What is Cerebrolysin?
Cerebrolysin is a porcine-derived neuropeptide mixture approved in over 40 countries for stroke recovery, TBI, and dementia. Meta-analyses report benefit in early stroke recovery and vascular dementia, but the largest single stroke trial, CASTA, missed its primary endpoint.
Overview
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue through controlled enzymatic proteolysis. It has been approved in over 40 countries (notably in Europe, Russia, China, and South Korea) for stroke recovery, traumatic brain injury, and dementia. Its randomized trial record is substantial by the standards of this category, though the largest stroke trial was neutral on its primary endpoint.
Mechanism of action
Cerebrolysin mimics the action of endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF). Its peptide fragments cross the blood-brain barrier and activate multiple neuroprotective and neuroregenerative pathways: inhibiting calpain-mediated neuronal death, reducing amyloid-beta aggregation (relevant to Alzheimer's), promoting neurogenesis and synaptogenesis, modulating GSK-3β activity, and reducing neuroinflammation. It acts on the PI3K/Akt survival pathway and inhibits apoptosis.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| cognitive enhancement / neuroprotection | intramuscular | 5–10 mL | daily | Standard protocol: 5-10mL IM daily for 10-20 days. Stroke protocols use higher IV doses (30-50mL). Repeat courses every 3-6 months. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Cerebrolysin research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
The largest stroke trial, CASTA (Heiss et al., Stroke 2012, n=1,070), did not meet its primary endpoint: the combined global test of modified Rankin Scale, Barthel Index and NIHSS showed no significant difference from placebo. A post hoc subgroup of severely affected patients (NIHSS above 12) showed a favorable trend, which the authors said needs confirmation in a further trial. A later meta-analysis of nine stroke trials (Bornstein et al., Neurol Sci 2018) did find a benefit on early NIHSS. In mild-to-moderate Alzheimer's, a meta-analysis of six trials found a cognitive benefit at 4 weeks that was no longer significant at 6 months. Traumatic brain injury evidence is limited to small pilot trials. Cerebrolysin is used extensively in post-Soviet and Asian clinical practice, and safety has been comparable to placebo across trials.[1][2][3][4][5][6][7][8]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Cerebrolysin for synergistic effects.
Legal status
Approved as a prescription drug in 40+ countries. Not FDA-approved. Classified as a biological product. Available through international pharmacies.
Sourcing & access
Prescription required
Cerebrolysin is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. It is approved in over 40 countries for stroke recovery, traumatic brain injury, and dementia, and is among the more extensively trialed neurotrophic treatments, though not FDA-approved.
Cerebrolysin is not FDA-approved but is approved as a prescription drug in over 40 countries including across Europe, Russia, China, and South Korea. It is classified as a biological product and is available through international pharmacies.
A meta-analysis of six randomized trials in mild-to-moderate Alzheimer's (Gauthier et al., 2015) found better cognitive scores at 4 weeks, but the cognitive difference was no longer statistically significant at 6 months. Global clinical change favored cerebrolysin at both time points. The amyloid and neurogenesis effects are from laboratory models, not from patients.
The standard protocol is 5 to 10 mL intramuscularly daily for 10 to 20 days, repeated every 3 to 6 months. Stroke protocols use higher intravenous doses of 30 to 50 mL.
Side effects include dizziness, headache, injection site pain, and rarely agitation, insomnia, or nausea. In the randomized trials and meta-analyses published to date, including CASTA (n=1,070) and the Bornstein 2018 pooled analysis, adverse event rates were comparable to placebo. Cerebrolysin is not FDA-approved, so it has not been through an FDA safety review.
Research references
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trialsPubMed
- Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezilPubMed
- Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled TrialsPubMed
- Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trialsPubMed
- Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trialPubMed
- Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA)PubMed
- Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trialPubMed
- Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized studyPubMed